title: Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.
authors.forename: M
authors.initials: M
authors.lastname: Engelhardt
authors.forename: A M S
authors.initials: AM
authors.lastname: Müller
authors.forename: W
authors.initials: W
authors.lastname: Maier
authors.forename: R
authors.initials: R
authors.lastname: Wäsch
mesh_terms: D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D006312:Hearing Loss, Bilateral / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib